Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease, Autoinflammatory, and Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-18 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | IL-18 Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed. |
View IL-18 Products |
| Antigen (Engineered) | IL-18 Mutant Panel (IL-18BP-resistant variants) Theoretical MW verified. For decoy-evasion drug development. |
View IL-18 Products |
| Receptor Alpha | IL-18R1 (IL-18Rα) ECD-Fc Fusion High purity (>95%), SPR/BLI validated sequence. |
View IL-18R1 Products |
| Accessory Protein | IL-18RAP (IL-18Rβ) ECD-Fc Fusion For heterodimeric receptor complex studies. |
View IL-18RAP Products |
| Decoy Target | IL-18BP (Binding Protein) Fc Fusion Critical for competitive binding assays. |
View IL-18BP Products |
| Gene Delivery | IL-18 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Codon-optimized. |
View IL-18 Products |
| Validator | IL-18 siRNA Set For knockdown verification and specificity controls. |
View IL-18 Products |
| Benchmark Ab | Anti-IL-18 (Clinical Biosimilar Sequence) Recombinant positive control. |
View IL-18 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| IL-18BP Competition / Decoy Evasion Screening | High-purity IL-18BP and IL-18R1 proteins available (>95%); Sequence-verified binding domains for accurate IC50 determination. HEK293 expressed for native glycosylation. |
| Species Cross-reactivity (Human/Mouse/Cyno translation) | Ortholog protein panel (Human, Mouse, Cynomolgus) with identical expression system (HEK293) to eliminate host-cell glycosylation artifacts. |
| Heterodimeric Receptor Binding (IL-18R1/RAP complex) | Matched receptor pair co-expressed and purified; Verified by mass spec for 1:1 stoichiometry. |
| Lack of Controls in Assay Baseline | Clinical Benchmark Antibodies (Biosimilars) included for assay baseline establishment. |
| False Positives in Functional Assays | Validated siRNA included for specificity checks; Endotoxin-controlled (<1 EU/µg) to eliminate LPS contamination artifacts. |
Live IL-18 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research (Decoy-Resistant)
- ➤ Latest Resistance Research (General)
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for IL-18 therapeutics is intensifying, driven by a bifurcated clinical strategy. In oncology, major players are shifting focus from traditional wild-type cytokines to engineered Decoy-Resistant IL-18 (DR-IL-18) modalities to bypass neutralization by the tumor microenvironment's abundant IL-18BP. First-generation IL-18 neutralizing antibodies are reaching Phase II for inflammatory indications (e.g., GSK1070806). Concurrently, the next wave of R&D is targeting IL-18 super-agonists (DR-18 analogs) for cancer immunotherapy and fibrotic diseases. In the autoinflammatory and autoimmune realm, developers prioritize ultra-high-affinity neutralizing monoclonal antibodies and IL-18BP fusion proteins (e.g., Tadekinig alfa) to suppress the inflammasome pathway. Emerging modalities include bispecifics (e.g., PD-1/IL-18), masked tumor-conditionally active cytokines, and immunocytokines to maximize therapeutic index and minimize systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Engineered Cytokine (Decoy-Resistant) | Simcha Therapeutics, Compass Therapeutics, Biotechs developing IL-18BP-resistant variants | Solid Tumors (Melanoma, Combo with PD-1) | IL-18BP Competition Assay (Need WT vs Mutant proteins; High-Purity IL-18BP and IL-18R1) |
| Neutralizing mAb | GSK, Sanofi, Immunology focused biopharma | Autoinflammatory Diseases, MAS, Inflammatory Bowel Disease | Affinity Maturation Assay (Need Native Glycosylated IL-18); Species Cross-reactivity Panel |
| Recombinant IL-18BP | AB2 Bio | HLH, Adult-onset Still's Disease | Ligand Blocking Assay (Need Endotoxin Controlled Antigens) |
| Receptor Antagonist | Early-stage biotech | Fibrosis, NAFLD | Heterodimer Binding (IL-18R1/RAP complex stability) |
| Gene Therapy | Academic/Startup programs | Localized Immuno-oncology | Lentivirus for Stable Cell Line (High-titer, sequence-verified) |
| Targeted Fusion / Bispecific | Roche, BioNTech | Advanced Malignancies | Heterodimer Validation (Need Sequence Verified Orthologs) |
Related Targets for Cross-Selling
Based on IL-18 signaling biology and clinical combination trends, recommend the following related targets:
- IL-12: Synergistic IFN-γ induction; dual-target fusion proteins.
- IL-37: Natural anti-inflammatory counterpart; counter-screening for IL-18-specific drugs.
- STING (STING1/TMEM173): Upstream activator of IL-18; combination with STING agonists.
- PD-1 / PD-L1: Core combination partner for IL-18 super-agonists in immuno-oncology.